Steven H Holtzman
CIK 1300247 · EVP Corporate Development · last filed 2026-06-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BIIB price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUDBURY, MA 01776
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CAMP | Director | 108,946 | $3.99 | $434.7K | $0 | 3 | 2026-06-12 |
| BIIB | EVP Corporate Development | 8,326 | $247.78 | $2.06M | -$4.22M | 24 | 2016-02-25 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Director | 3,945 | $0.04 | $176 | -$3.14M | 15 | 2012-06-04 |
| ANADYS PHARMACEUTICALS INC (ANDS) Delisted | Director | — | — | — | $0 | 6 | 2010-05-28 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| INFI | Direct | 0 | 0.0% | 2012-06-04 |
| Holtzman-Stewart 1996 Irrevocable Trust and included in the reporting person's prior ownership reports By IRA |
3,945 | 100.0% | 2012-06-04 | |
| Total | 3,945 | |||
| No longer reported | ||||
| By Holtzman-Stewart 1996 Irrevocable Trust | 177,364 | — | last 2012-05-31 | |
Recent Filings · Page 3 of 5
48 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-09-18 | BIIB | Sell (S) | −3,501 | -$836.7K | EDGAR |
| 2013-02-14 | BIIB | Grant (A) | — | $0 | EDGAR |
| 2013-02-12 | BIIB | Mixed | +1,404 | -$154.6K | EDGAR |
| 2013-02-05 | BIIB | Mixed | +3,481 | -$263.9K | EDGAR |
| 2012-06-04 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Sell (S) | −57,573 | -$749.0K | EDGAR |
| 2012-05-31 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Mixed | −215,261 | -$2.60M | EDGAR |
| 2012-05-18 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-02-10 | BIIB | Grant (A) | — | $0 | EDGAR |
| 2012-02-03 | BIIB | Mixed | +3,501 | -$201.0K | EDGAR |
| 2011-05-19 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Grant (A) | — | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).